Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 15/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNG2 | P59768 | 1/20 | 0.50 |
| ▸ | GNB1 | P62873 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079067 | 0.91 | TERT (0.66) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL4074842 | 0.86 | TERT (0.91) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL4076947 | 0.83 | TERT (0.65) | TERTDOT1L | |
| SCHEMBL27890181 | 0.79 | TERT (0.69) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL6339837 | 0.79 | TERT (0.78) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL4077093 | 0.78 | TERT (0.86) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL6765226 | 0.78 | TERT (1.00) | TERTDOT1L | |
| SCHEMBL4083568 | 0.77 | TERT (0.62) | TERTDOT1L | |
| SCHEMBL4748820 | 0.76 | ALDH1A1 (0.66) | TERTDOT1LMEN1MMP1MMP9 | |
| SCHEMBL4081851 | 0.76 | TERT (0.64) | TERTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | claimed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | claimed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | TERT 43/4885DOT1L 1150/4885MEN1 3983/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | TERT 196/4885DOT1L 1385/4885MEN1 4234/4885 |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | DPYD, NTPCR, NME1 | TERT 196/4885DOT1L 1385/4885MEN1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.